Identification and antibiotic sensitivity test of isolated aerobic bacteria from acne vulgaris

Lily Suciati; Iman Santoso; Qonita Gina Fadhilah; Sogandi Sogandi

doi:10.35814/jifi.v24i1.1589

Authors

Lily Suciati Faculty of Pharmacy, University of 17 August 1945, North Jakarta, 14350, Indonesia ,
Iman Santoso Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, West Java, 16424, Indonesia
Qonita Gina Fadhilah Faculty of Pharmacy, University of 17 August 1945, North Jakarta, 14350, Indonesia ,
Sogandi Sogandi Faculty of Pharmacy, University of 17 August 1945, North Jakarta, 14350, Indonesia ,

DOI:

https://doi.org/10.35814/jifi.v24i1.1589

Keywords:

Acne vulgaris, aerobic bacteria, antibiotic sensitivity, identification, isolation

Abstract

Acne vulgaris is an inflammatory skin condition caused by various factors, including bacteria in the sebaceous glands of the dermis. Inflammation in acne vulgaris can lead to the formation of purulent papules, known as acne papulopustulosa. Treatment options for acne vulgaris include topical antibiotics, such as clindamycin, and oral antibiotics, such as tetracycline, minocycline, and doxycycline. This study aimed to isolate and identify aerobic bacteria associated with acne vulgaris and assess their susceptibility to commonly used antibiotics. Aerobic bacteria from the papulopustules of six patients were isolated using the quadrant streak method on Mueller Hinton Agar (MHA) and Mannitol Salt Agar (MSA). Twelve isolates were obtained, characterized using Gram staining, catalase, and oxidase tests, and identified by 16S rRNA sequencing. The most common bacteria were Staphylococcus spp. (five patients), followed by Klebsiella sp. (two patients), Enterobacter sp. (one patient), and Citrobacter sp. (one patient). Sensitivity testing was conducted with tetracycline, minocycline, doxycycline, and clindamycin, following the Clinical Laboratory Standards Institute (CLSI) guidelines. The results showed that the effectiveness of tetracycline was 50.0%, minocycline 58.3%, and doxycycline 58.3%, while all isolates were resistant to clindamycin. Due to the small sample size, the findings should be interpreted as preliminary and descriptive, providing exploratory insight into the diversity of aerobic bacteria in acne lesions and their antibiotic susceptibility.

References

[1] M. Vasam, S. Korutla, and R. A. Bohara, “Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances,” Biochem Biophys Rep, vol. 36, p. 101578, Dec. 2023, doi: 10.1016/j.bbrep.2023.101578.

[2] H. J. Kim and Y. H. Kim, “Exploring acne treatments: from pathophysiological mechanisms to emerging therapies,” Int J Mol Sci, vol. 25, no. 10, p. 5302, May 2024, doi: 10.3390/ijms25105302.

[3] A. H. Sutaria, S. Masood, H. M. Saleh, and J. Schlessinger, “Acne Vulgaris.” Accessed: Feb. 14, 2025. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459173/

[4] R. M. Jaber, B. M. Alnshash, S. N. Mousa, H. S. Fayoumi, L. M. Al-Qaderi, and A. M. Zant, “The epidemiology of acne vulgaris among adolescents and young adults in Jordan University hospital,” Open J Nurs, vol. 10, no. 04, pp. 353–366, 2020, doi: 10.4236/ojn.2020.104024.

[5] J. Kaikati et al., “The impact of acne treatment on quality of life and self-esteem: A prospective cohort study from Lebanon,” Int J Womens Dermatol, vol. 7, no. 4, pp. 415–421, Sep. 2021, doi: 10.1016/j.ijwd.2021.03.005.

[6] C. Stamu‐O’Brien, M. Jafferany, S. Carniciu, and A. Abdelmaksoud, “Psychodermatology of acne: Psychological aspects and effects of acne vulgaris,” J Cosmet Dermatol, vol. 20, no. 4, pp. 1080–1083, Apr. 2021, doi: 10.1111/jocd.13765.

[7] T. Y. Huang, Y. E. Jiang, and D. A. Scott, “Culturable bacteria in the entire acne lesion and short-chain fatty acid metabolites of Cutibacterium acnes and Staphylococcus epidermidis isolates,” Biochem Biophys Res Commun, vol. 622, pp. 45–49, Sep. 2022, doi: 10.1016/j.bbrc.2022.06.068.

[8] Y. Deng, F. Wang, and L. He, “Skin barrier dysfunction in acne vulgaris: Pathogenesis and therapeutic approaches,” Med Sci Monit, vol. 30, Oct. 2024, doi: 10.12659/MSM.945336.

[9] I. Cavallo et al., “Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents,” Sci Rep, vol. 12, no. 1, p. 21104, Dec. 2022, doi: 10.1038/s41598-022-25436-3.

[10] B. Dreno et al., “Acne microbiome: From phyla to phylotypes,” J Eur Acad Dermatol Venereol, vol. 38, no. 4, pp. 657–664, Apr. 2024, doi: 10.1111/jdv.19540.

[11] Y. Ito and M. Amagai, “Controlling skin microbiome as a new bacteriotherapy for inflammatory skin diseases,” Inflamm Regen, vol. 42, no. 1, p. 26, Sep. 2022, doi: 10.1186/s41232-022-00212-y.

[12] Clinical and Laboratory Standards Institute (CLSI), “M100 Performance Standards for Anti-Microbial Susceptibility Testing. 27th edition.” Accessed: Nov. 17, 2024. [Online]. Available: https://goums.ac.ir/files/deputy_treat/md_labs_ef39a/files/M100-S27_CLSI_2017.pdf

[13] J. Paleczny et al., “The medium composition ımpacts Staphylococcus aureus biofilm formation and susceptibility to antibiotics applied in the treatment of bone ınfections,” Int J Mol Sci, vol. 23, no. 19, p. 11564, Sep. 2022, doi: 10.3390/ijms231911564.

[14] A. Wanger, V. Chavez, R. S. P. Huang, A. Wahed, J. K. Actor, and A. Dasgupta, “Media for the Clinical Microbiology Laboratory,” in Microbiology and Molecular Diagnosis in Pathology, Elsevier, 2017, pp. 51–60. doi: 10.1016/B978-0-12-805351-5.00004-1.

[15] Liofilchem, “Tryptic Soy Broth Casein Soya Beas Digest Broth,” Accessed: Feb. 17, 2025. [Online]. Available: https://www.liofilchem.net/login/pd/ifu/24513_IFU.pdf

[16] O. D. Festus and O. O. Emmanuella, “Testing the efficacy of Mueller Hinton agar over Nutrient agar for optimal antibiotic sensitivity testing response by selected clinical bacterial pathogens,” GSC Adv Res Rev, vol. 5, no. 2, pp. 061–074, Nov. 2020, doi: 10.30574/gscarr.2020.5.2.0037.

[17] C. Shen and Y. Zhang, “Isolation of Foodborne Pathogens on Selective, Differential, and Enrichment Medium by Streak-Plating,” in Food Microbiology Laboratory for the Food Science Student, Cham: Springer International Publishing, 2023, pp. 25–30. doi: 10.1007/978-3-031-26197-8_4.

[18] C. P. Davis, “Normal Flora.” Accessed: Dec. 11, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK7617/

[19] Y. Zhu, X. Yu, and G. Cheng, “Human skin bacterial microbiota homeostasis: A delicate balance between health and disease,” mLife, vol. 2, no. 2, pp. 107–120, Jun. 2023, doi: 10.1002/mlf2.12064.

[20] I. B. S. Sitohang, H. Fathan, E. Effendi, and M. Wahid, “The susceptibility of pathogens associated with acne vulgaris to antibiotics,” Med J Indonesia, vol. 28, no. 1, pp. 21–7, May 2019, doi: 10.13181/mji.v28i1.2735.

[21] N. Zhao et al., “Molecular characteristics of Staphylococcus aureus isolates colonizing human nares and skin,” Med Microecol, vol. 7, p. 100031, Mar. 2021, doi: 10.1016/j.medmic.2020.100031.

[22] L. Legiawati, P. A. Halim, M. Fitriani, H. G. Hikmahrachim, and H. W. Lim, “Microbiomes in acne vulgaris and their susceptibility to antibiotics in Indonesia: A systematic review and meta-analysis,” Antibiotics, vol. 12, no. 1, p. 145, Jan. 2023, doi: 10.3390/antibiotics12010145.

[23] C. Dessinioti and A. Katsambas, “The microbiome and acne: Perspectives for treatment,” Dermatol Ther (Heidelb), vol. 14, no. 1, pp. 31–44, Jan. 2024, doi: 10.1007/s13555-023-01079-8.

[24] A. Abdulatif, “Antibiotics resistance and susceptibility pattern of Staphylococcus aureus and Staphylococcus epidermidis associated with acne,” AlQalam J Med App Sci, vol. 6, no. 2, pp. 687–693, 2023.

[25] A. RAHMANI, L. MERADI, K. MALAWI, and F. KHANFOUF, “Phenotypic characterization of antimicrobial drug resistance of Staphylococcus aureus and S. epidermidis strains isolated from various community infections in Oum El Bouaghi city, Algeria,” Biodiversitas, vol. 22, no. 5, Apr. 2021, doi: 10.13057/biodiv/d220526.

[26] P. Hassanzadeh, M. Bahmani, and D. Mehrabani, “Bacterial resistance to antibiotics in acne vulgaris: An in vitro study,” Indian J Dermatol, vol. 53, no. 3, p. 122, 2008, doi: 10.4103/0019-5154.43213.

[27] A. Asditya, I. Zulkarnain, and A. Nurul Hidayati, “Uji kepekaan antibiotik oral terhadap bakteri Propionilbacterium acnes pasien akne vulgaris derajat sedang berat (oral antimicrobial susceptibility of Propionilbacterium acnes in moderate severe acne vulgaris patient’s),” Berkala Ilmu Kesehatan Kulit dan Kelamin, vol. 31, no. 3, pp. 228–235, 2019, doi: 10.20473/bikk.V31.3.2019.128-135.

[28] M. K. Armillei, I. B. Lomakin, J. Q. Del Rosso, A. Grada, and C. G. Bunick, “Scientific rationale and clinical basis for clindamycin use in the treatment of dermatologic disease,” Antibiotics, vol. 13, no. 3, p. 270, Mar. 2024, doi: 10.3390/antibiotics13030270.

[29] H. Baldwin, “Oral Antibiotic Treatment Options for Acne Vulgaris.,” J Clin Aesthet Dermatol, vol. 13, no. 9, pp. 26–32, Sep. 2020.

[30] P. B. Murphy, K. G. Bistas, P. Patel, and J. K. Le, Clindamycin. 2024. Accessed: Jan. 17, 2025. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK519574/

[31] N. M. Pelet del Toro et al., “Topical clindamycin for acne vulgaris: analysis of gastrointestinal events,” J Dermatol Treat, vol. 35, no. 1, Dec. 2024, doi: 10.1080/09546634.2024.2325603.

[32] E. Scholar, “Tetracycline,” in xPharm: The Comprehensive Pharmacology Reference, Elsevier, 2007, pp. 1–6. doi: 10.1016/B978-008055232-3.62736-9.

[33] A. Rusu and E. L. Buta, “The development of third-generation tetracycline antibiotics and new perspectives,” Pharmaceutics, vol. 13, no. 12, p. 2085, Dec. 2021, doi: 10.3390/pharmaceutics13122085.

[34] V. Barrenechea, M. Vargas-Reyes, M. Quiliano, and P. Milón, “A complementary mechanism of bacterial mRNA translation ınhibition by tetracyclines,” Front Microbiol, vol. 12, Jun. 2021, doi: 10.3389/fmicb.2021.682682.

[35] N. O. Eltai, A. A. Al Thani, S. H. Al Hadidi, K. Al Ansari, and H. M. Yassine, “Antibiotic resistance and virulence patterns of pathogenic Escherichia coli strains associated with acute gastroenteritis among children in Qatar,” BMC Microbiol, vol. 20, no. 1, p. 54, Dec. 2020, doi: 10.1186/s12866-020-01732-8.

[36] R. Timsina, U. Shrestha, A. Singh, and B. Timalsina, “Inducible clindamycin resistance and erm genes in Staphylococcus aureus in school children in Kathmandu, Nepal.,” Future Sci OA, vol. 7, no. 1, p. FSO361, Oct. 2020, doi: 10.2144/fsoa-2020-0092.

[37] C. Kenyon et al., “Doxycycline PEP can induce doxycycline resistance in Klebsiella pneumoniae in a Galleria mellonella model of PEP.,” Front Microbiol, vol. 14, p. 1208014, 2023, doi: 10.3389/fmicb.2023.1208014.

[38] S. R. Connell, D. M. Tracz, K. H. Nierhaus, and D. E. Taylor, “Ribosomal protection proteins and their mechanism of tetracycline resistance.,” Antimicrob Agents Chemother, vol. 47, no. 12, pp. 3675–81, Dec. 2003, doi: 10.1128/AAC.47.12.3675-3681.2003.

[39] A. J. Gasparrini et al., “Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic bacteria cause broad-spectrum tetracycline resistance.,” Commun Biol, vol. 3, no. 1, p. 241, May 2020, doi: 10.1038/s42003-020-0966-5.